After finishing at $129.70 in the prior trading day, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $118.90, down -8.33%. In other words, the price has decreased by -$10.80 from its previous closing price. On the day, 2253166 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of JAZZ by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.02. For the most recent quarter (mrq), Quick Ratio is recorded 1.85 and its Current Ratio is at 2.24. In the meantime, Its Debt-to-Equity ratio is 1.55 whereas as Long-Term Debt/Eq ratio is at 1.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $160.
On November 27, 2023, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $170 to $135.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 when Smith Mark Douglas sold 417 shares for $119.27 per share. The transaction valued at 49,736 led to the insider holds 6,888 shares of the business.
Cook Jennifer E. sold 417 shares of JAZZ for $49,736 on Dec 04. The Director now owns 6,888 shares after completing the transaction at $119.27 per share. On Sep 01, another insider, Patil Neena M, who serves as the EVP & Chief Legal Officer of the company, sold 1,500 shares for $144.25 each. As a result, the insider received 216,375 and left with 29,186 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 8.17B and an Enterprise Value of 12.37B. As of this moment, Jazz’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.36, and their Forward P/E ratio for the next fiscal year is 5.62. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95 while its Price-to-Book (P/B) ratio in mrq is 1.98. Its current Enterprise Value per Revenue stands at 3.26 whereas that against EBITDA is 15.20.
Stock Price History:
Over the past 52 weeks, JAZZ has reached a high of $147.98, while it has fallen to a 52-week low of $111.25. The 50-Day Moving Average of the stock is 123.51, while the 200-Day Moving Average is calculated to be 127.90.
Shares Statistics:
The stock has traded on average 569.30K shares per day over the past 3-months and 498.77k shares per day over the last 10 days, according to various share statistics. A total of 63.21M shares are outstanding, with a floating share count of 60.97M. Insiders hold about 3.15% of the company’s shares, while institutions hold 91.86% stake in the company. Shares short for JAZZ as of Feb 15, 2024 were 2.32M with a Short Ratio of 4.08, compared to 2.16M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.69% and a Short% of Float of 4.25%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of $4.38 for the current quarter, with a high estimate of $4.9 and a low estimate of $3.54, while EPS last year was $3.95. The consensus estimate for the next quarter is $4.84, with high estimates of $5.33 and low estimates of $4.21.
Analysts are recommending an EPS of between $24.32 and $16.83 for the fiscal current year, implying an average EPS of $19.94. EPS for the following year is $21.97, with 13 analysts recommending between $28.28 and $18.17.
Revenue Estimates
10 analysts predict $953.03M in revenue for the current quarter. It ranges from a high estimate of $980M to a low estimate of $912.7M. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $892.81M, an estimated increase of 6.70% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $1.01B, an increase of 5.10% less than the figure of $6.70% in the same quarter last year. There is a high estimate of $1.03B for the next quarter, whereas the lowest estimate is $983.53M.
A total of 18 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.56B, while the lowest revenue estimate was $3.93B, resulting in an average revenue estimate of $4.09B. In the same quarter a year ago, actual revenue was $3.83B, up 6.60% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $4.31B in the next fiscal year. The high estimate is $5.07B and the low estimate is $2.92B. The average revenue growth estimate for next year is up 5.40% from the average revenue estimate for this year.
